var data={"title":"Management and outcome of sepsis in term and late preterm infants","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Management and outcome of sepsis in term and late preterm infants</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/contributors\" class=\"contributor contributor_credentials\">Leonard E Weisman, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/contributors\" class=\"contributor contributor_credentials\">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/contributors\" class=\"contributor contributor_credentials\">Carrie Armsby, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 31, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sepsis is an important cause of morbidity and mortality among newborn infants. Although the incidence of sepsis in term and late preterm infants is low, the potential for serious adverse outcomes, including death, is of such great consequence that caregivers should have a low threshold for evaluation and treatment for possible sepsis in neonates. The approach discussed below is consistent with guidelines published by the American Academy of Pediatrics (AAP) and the Centers for Disease Control and Prevention (CDC) [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p>The treatment and outcome of sepsis in term and late preterm infants will be reviewed here. The epidemiology, clinical features, diagnosis, and evaluation of sepsis in term and late preterm infants, neonatal sepsis in preterm infants, the management of well-appearing infants at risk for group B streptococcal (GBS) infection, and the evaluation of febrile or ill-appearing newborns are discussed separately:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation\" class=\"medical medical_review\">&quot;Treatment and prevention of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis\" class=\"medical medical_review\">&quot;Management of the infant whose mother has received group B streptococcal chemoprophylaxis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=febrile-infant-younger-than-90-days-of-age-management#H3920033265\" class=\"medical medical_review\">&quot;Febrile infant (younger than 90 days of age): Management&quot;, section on 'Neonates (28 days of age and younger)'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=approach-to-the-ill-appearing-infant-younger-than-90-days-of-age\" class=\"medical medical_review\">&quot;Approach to the ill-appearing infant (younger than 90 days of age)&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">TERMINOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following terms will be used throughout this discussion on neonatal sepsis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Neonatal sepsis</strong> is a clinical syndrome in an infant 28 days of life or younger, manifested by systemic signs of infection and isolation of a bacterial pathogen from the bloodstream [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/3\" class=\"abstract_t\">3</a>]. A consensus definition for neonatal sepsis is lacking [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H19\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Term infants</strong> are those born at a gestational age of 37 weeks or greater.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Late preterm infants</strong> (also called near-term infants) are those born from 34 through 36 completed weeks of gestation [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=late-preterm-infants\" class=\"medical medical_review\">&quot;Late preterm infants&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Preterm infants</strong> are those born at less than 34 weeks of gestation [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/5\" class=\"abstract_t\">5</a>].</p><p/><p>Neonatal sepsis is classified according to the infant's age at the onset of symptoms:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Early-onset sepsis</strong> is defined as the onset of symptoms before 7 days of age, although some experts limit the definition to infections occurring within the first 72 hours of life [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/6\" class=\"abstract_t\">6</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Late-onset sepsis</strong> is defined as the onset of symptoms at &ge;7 days of age [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/6\" class=\"abstract_t\">6</a>]. Similarly to early-onset sepsis, there is variability in its definition, ranging from an onset at &gt;72 hours of life to &ge;7 days of age [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/6,7\" class=\"abstract_t\">6,7</a>].</p><p/><p class=\"headingAnchor\" id=\"H341853\"><span class=\"h1\">SUPPORTIVE CARE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Symptomatic infants should be treated in a care setting with full cardiopulmonary monitoring and support, because the clinical course of these infants can deteriorate rapidly. Although there are no data demonstrating the importance of supportive care measures in neonates with sepsis, it is generally accepted that the following supportive measures are critical components of management:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Maintaining adequate oxygenation and perfusion (see <a href=\"topic.htm?path=noninvasive-oxygen-delivery-and-oxygen-monitoring-in-the-newborn\" class=\"medical medical_review\">&quot;Noninvasive oxygen delivery and oxygen monitoring in the newborn&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prevention of hypoglycemia and metabolic acidosis (see <a href=\"topic.htm?path=management-and-outcome-of-neonatal-hypoglycemia\" class=\"medical medical_review\">&quot;Management and outcome of neonatal hypoglycemia&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Maintenance of normal fluid and electrolyte status (see <a href=\"topic.htm?path=fluid-and-electrolyte-therapy-in-newborns\" class=\"medical medical_review\">&quot;Fluid and electrolyte therapy in newborns&quot;</a>)</p><p/><p>Severely ill patients may require ventilatory, volume, <span class=\"nowrap\">and/or</span> vasopressor support to maintain adequate oxygenation and perfusion. (See <a href=\"topic.htm?path=mechanical-ventilation-in-neonates\" class=\"medical medical_review\">&quot;Mechanical ventilation in neonates&quot;</a> and <a href=\"topic.htm?path=etiology-clinical-manifestations-evaluation-and-management-of-neonatal-shock\" class=\"medical medical_review\">&quot;Etiology, clinical manifestations, evaluation, and management of neonatal shock&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H943510014\"><span class=\"h1\">ONGOING DIAGNOSTIC EVALUATION</span></p><p class=\"headingAnchor\" id=\"H878363033\"><span class=\"h2\">Other diagnostic considerations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In infants with suspected sepsis, additional testing for other conditions may be warranted based on clinical signs and symptoms (<a href=\"image.htm?imageKey=PEDS%2F100409\" class=\"graphic graphic_table graphicRef100409 \">table 1</a>). It is often difficult to differentiate neonatal sepsis from other diseases; however, given the morbidity and mortality of neonatal sepsis, empiric antibiotic therapy should be provided (after cultures are obtained) to infants with suspected sepsis, pending definitive culture-based diagnosis. Alternative diagnoses should be entertained when an infant with suspected sepsis has negative cultures. (See <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H22\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Differential diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H943510021\"><span class=\"h2\">Lumbar puncture</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If not done during the initial evaluation, a lumbar puncture (LP) should be performed in infants, whenever possible, with culture-proven or culture-negative clinical sepsis. Clinical signs suggesting meningitis can be lacking, and blood culture may be negative in infants with meningitis. (See <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Clinical features and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">ANTIBIOTIC THERAPY</span></p><p class=\"headingAnchor\" id=\"H943509421\"><span class=\"h2\">Whom to treat</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The decision to start antibiotic therapy is based on assessment of risk factors, clinical evaluation, and laboratory tests. Indications for empiric antibiotic therapy include (see <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H12\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Evaluation and initial management'</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ill-appearance (see <a href=\"topic.htm?path=approach-to-the-ill-appearing-infant-younger-than-90-days-of-age\" class=\"medical medical_review\">&quot;Approach to the ill-appearing infant (younger than 90 days of age)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Concerning symptoms, including temperature instability, or respiratory, cardiocirculatory, or neurologic symptoms (see <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H8\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Clinical manifestations'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cerebrospinal fluid (CSF) pleocytosis (white blood cell [WBC] cell count of &gt;20 to 30 <span class=\"nowrap\">cells/microL)</span> (<a href=\"image.htm?imageKey=PEDS%2F54464\" class=\"graphic graphic_table graphicRef54464 \">table 2</a>) (see <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-clinical-features-and-diagnosis#H12\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Clinical features and diagnosis&quot;, section on 'Interpretation of CSF'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Confirmed or suspected maternal chorioamnionitis (see <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H96556694\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Maternal risk factors'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Positive blood, urine, or CSF culture (see <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H15\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Blood culture'</a>)</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Initial empiric therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The initial choice of parenteral antimicrobials for suspected sepsis in term and late preterm neonates is based on the infant's age, likely pathogens, the susceptibility patterns of organisms in a particular nursery, and the presence of an apparent source of infection (eg, skin, joint, or bone involvement) (<a href=\"image.htm?imageKey=PEDS%2F102574\" class=\"graphic graphic_table graphicRef102574 \">table 3</a>).</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">Early-onset sepsis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The recommended empiric regimen for suspected early-onset sepsis in a term or late preterm infant is <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> 150 <span class=\"nowrap\">mg/kg</span> per dose intravenously (IV) every 12 hours and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> 4 <span class=\"nowrap\">mg/kg</span> per dose IV every 24 hours [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/7,8\" class=\"abstract_t\">7,8</a>]. We generally obtain baseline renal function tests (ie, blood urea nitrogen and creatinine levels) at the initiation of treatment with gentamicin. Serum gentamicin levels should be obtained in infants receiving a full course of antibiotics but are not required if a treatment course of only 48 hours is anticipated and renal function is normal [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/3,7\" class=\"abstract_t\">3,7</a>].</p><p>The combination of <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> is effective in treating most common pathogens that cause early-onset sepsis, including group B <em>Streptococcus</em> (GBS), <em>Listeria</em>, <em>Enterococcus</em>, and most isolates of <em>Escherichia coli</em> (<a href=\"image.htm?imageKey=PEDS%2F61061\" class=\"graphic graphic_table graphicRef61061 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/1,9\" class=\"abstract_t\">1,9</a>].</p><p>In a national surveillance study (2006 to 2008), 94 percent of all isolates in neonates were susceptible to the combination of penicillin and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/10\" class=\"abstract_t\">10</a>]. In a 10-year review from a single center, 90 percent of early-onset sepsis pathogens in term and late preterm infants were susceptible to <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> <span class=\"nowrap\">and/or</span> gentamicin [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/11\" class=\"abstract_t\">11</a>]. Among six infants with early-onset <em>Staphylococcus aureus</em> bacteremia that was not susceptible to ampicillin and gentamicin, there were no complications before or after antibiotic therapy was adjusted, based upon antibiotic susceptibility.</p><p><a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">Ampicillin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> are preferred over ampicillin and a third-generation cephalosporin (eg, <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a>), based upon the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The regimen of <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> and a third-generation cephalosporin is not more effective than the combination of ampicillin and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/12\" class=\"abstract_t\">12</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The emergence of cephalosporin-resistant gram-negative organisms (eg, <em>Enterobacter cloacae</em>, <em>Klebsiella</em>, and <em>Serratia</em> species) can occur when <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a> is used routinely [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/1,13\" class=\"abstract_t\">1,13</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">Ampicillin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> are synergistic in treating infections caused by GBS and <em>Listeria monocytogenes</em>. Cephalosporins are <strong>not</strong> active against <em>L. monocytogenes</em>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a large cohort study, infants who received <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> plus <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a> had a 1.5-fold increase in mortality compared with those treated with ampicillin plus <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> (4.2 versus 1.9 percent, adjusted odds ratio [OR] 1.5, 95% CI 1.4-1.7) [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/12\" class=\"abstract_t\">12</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">Ceftriaxone</a> is highly bound to albumin and appears to displace bilirubin [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/14,15\" class=\"abstract_t\">14,15</a>]. Although displacement of free bilirubin by ceftriaxone has not been reported, avoidance of ceftriaxone in neonates at risk for acute bilirubin encephalopathy is recommended [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/1\" class=\"abstract_t\">1</a>]. </p><p/><p>The addition of a third-generation cephalosporin to the regimen of <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> is warranted for infants with suspected meningitis and critically ill neonates with risk factors associated with ampicillin-resistant infections (ie, prolonged rupture of membranes <span class=\"nowrap\">and/or</span> prolonged antenatal maternal ampicillin treatment).</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Late-onset sepsis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The choice of empiric therapy for late-onset sepsis depends upon whether the infant is admitted from the community and thus is at lower risk for infection caused by a multidrug-resistant pathogen or is hospitalized since birth and thus at a higher risk.</p><p class=\"headingAnchor\" id=\"H943509792\"><span class=\"h4\">Admitted from the community</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neonates admitted from the community are at lower risk for infection caused by a multidrug-resistant pathogen than are infants who remain hospitalized since birth. The combination of <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> or ampicillin and a third-generation cephalosporin (eg, <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a>, if available) are regimens for empiric treatment of sepsis without an apparent focus of infection in this setting (<a href=\"image.htm?imageKey=PEDS%2F102574\" class=\"graphic graphic_table graphicRef102574 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/6\" class=\"abstract_t\">6</a>].</p><p><a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">Ampicillin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> is generally the preferred regimen; however, local antibiotic resistance patterns must be considered. The dosing for ampicillin is 75 <span class=\"nowrap\">mg/kg</span> per dose IV every six hours; the dosing of gentamicin is 4 <span class=\"nowrap\">mg/kg</span> per dose IV every 24 hours [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/7,8\" class=\"abstract_t\">7,8</a>]. We generally obtain baseline renal function tests (ie, blood urea nitrogen and creatinine levels) at the initiation of treatment with gentamicin. Serum gentamicin levels should be obtained in infants receiving a full course of antibiotics but are not required if a treatment course of only 48 hours is anticipated and renal function is normal [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/3,7\" class=\"abstract_t\">3,7</a>].</p><p>In a national surveillance study (2006 to 2008), 96 percent of isolates from late-onset bacteremia were susceptible to the combination of <a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/10\" class=\"abstract_t\">10</a>]. The addition of a third-generation cephalosporin to an <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> and gentamicin regimen is warranted for neonates with suspected meningitis. (See <a href=\"#H943509807\" class=\"local\">'Special circumstances'</a> below.)</p><p class=\"headingAnchor\" id=\"H943509801\"><span class=\"h4\">Hospitalized since birth</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infants who continue to be hospitalized since birth are at higher risk for multidrug-resistant organisms, and therefore, <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> is substituted for <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> (<a href=\"image.htm?imageKey=PEDS%2F102574\" class=\"graphic graphic_table graphicRef102574 \">table 3</a>). For term infants &gt;7 days of life, the dosing of vancomycin is dependent on serum creatinine (Scr) [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/16\" class=\"abstract_t\">16</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Scr &lt;0.7 <span class=\"nowrap\">mg/dL</span> &ndash; 15 <span class=\"nowrap\">mg/kg/dose</span> IV every 12 hours</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Scr 0.7 to 0.9 <span class=\"nowrap\">mg/dL</span> &ndash; 20 <span class=\"nowrap\">mg/kg/dose</span> IV every 24 hours</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Scr 1 to 1.2 <span class=\"nowrap\">mg/dL</span> &ndash; 15 <span class=\"nowrap\">mg/kg/dose</span> IV every 24 hours</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Scr 1.3 to 1.6 <span class=\"nowrap\">mg/dL</span> &ndash; 10 <span class=\"nowrap\">mg/kg/dose</span> IV every 24 hours</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Scr &gt;1.6 <span class=\"nowrap\">mg/dL</span> &ndash; 15 <span class=\"nowrap\">mg/kg/dose</span> IV every 48 hours</p><p/><p>Alternative weight-directed neonatal dosing recommendations for <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> in are also available (refer to Lexicomp pediatric drug information).</p><p class=\"headingAnchor\" id=\"H943509807\"><span class=\"h3\">Special circumstances</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Alternative regimens based upon specific clinical circumstances include the following (<a href=\"image.htm?imageKey=PEDS%2F102574\" class=\"graphic graphic_table graphicRef102574 \">table 3</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Suspected meningitis</strong> &ndash; In neonates with late-onset sepsis in whom the lumbar puncture (LP) suggests meningitis (eg, CSF pleocytosis), a third-generation cephalosporin (eg, <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a>, if available) should be included in the regimen. Cefotaxime should also be added to the empiric regimen for early-onset meningitis if the CSF Gram stain reveals gram-negative bacilli. Cefotaxime provides extended spectrum for enteric gram-negative rods and has optimal activity in the CSF against pneumococci. If cefotaxime is not available, alternative agents include <a href=\"topic.htm?path=ceftazidime-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftazidime</a>, <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a> (not to be used in infants with clinically significant hyperbilirubinemia or those receiving concurrent IV calcium [including parenteral nutrition]), or <a href=\"topic.htm?path=meropenem-pediatric-drug-information\" class=\"drug drug_pediatric\">meropenem</a>. Meropenem is preferred if there is concern for infection due to a multidrug-resistant gram-negative organism. Treatment of bacterial meningitis in neonates is discussed in detail separately. (See <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome#H4\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Treatment and outcome&quot;, section on 'Empiric therapy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Suspected pneumonia</strong> &minus; Empiric regimens for treatment of infants with a pulmonary focus of infection include <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a>, ampicillin and a third-generation cephalosporin (eg, <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a>, if available), <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> and cefotaxime (if available), or vancomycin and gentamicin. Treatment of pneumonia in neonates is discussed in detail separately. (See <a href=\"topic.htm?path=neonatal-pneumonia#H24\" class=\"medical medical_review\">&quot;Neonatal pneumonia&quot;, section on 'Treatment'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Skin, soft tissue, bone, and joint infections</strong> &ndash; If there is a focus of infection involving the skin, soft tissues, bone, or joints (in which case <em>S. aureus</em> is a likely pathogen), <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> should be substituted for <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/17\" class=\"abstract_t\">17</a>]. In a toxic-appearing infant, <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a> should also be added.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Catheter-related infection</strong> &ndash; If intravascular catheter-related infection is a concern, treatment should be initiated with <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> to provide empiric coverage for coagulase-negative staphylococci, <em>S. aureus</em>, and gram-negative bacteria.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Suspected intestinal source </strong>&ndash; If infection is thought to arise from the gastrointestinal tract (eg, anaerobic bacteria), <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a> or another suitable agent, such as <a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">metronidazole</a>, should be added to the therapeutic regimen to improve coverage for these pathogens.</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Culture-proven sepsis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In neonates with culture-proven sepsis, the usual course of therapy is 10 days [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/1,3,13,18,19\" class=\"abstract_t\">1,3,13,18,19</a>]. Longer treatment courses may be warranted if a specific focus of infection is identified (eg, meningitis, osteomyelitis, or septic arthritis). Antimicrobial therapy should be altered based upon the susceptibility profile of the pathogen isolated.</p><p class=\"headingAnchor\" id=\"H18750256\"><span class=\"h3\">Pathogen-specific therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For the most common causative organisms of neonatal sepsis, antimicrobial therapy is as follows (<a href=\"image.htm?imageKey=PEDS%2F102574\" class=\"graphic graphic_table graphicRef102574 \">table 3</a>):</p><p class=\"headingAnchor\" id=\"H943510209\"><span class=\"h4\">Group B Streptococcus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The drug of choice for group B <em>Streptococcus</em> (GBS) is penicillin. Thus, when GBS is identified and resolution of bacteremia is documented by a repeat blood culture and in infants with meningitis the CSF is sterile, we recommend discontinuing <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> and continuing therapy with <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">penicillin G</a> alone (<a href=\"image.htm?imageKey=ID%2F66906\" class=\"graphic graphic_table graphicRef66906 \">table 5</a>). (See <a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants#H29\" class=\"medical medical_review\">&quot;Group B streptococcal infection in neonates and young infants&quot;, section on 'Definitive therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H943510215\"><span class=\"h4\">Escherichia coli</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with ampicillin-sensitive <em>Escherichia coli</em> (<em>E. coli</em>) sepsis who have improved clinically and in whom meningitis has been excluded, <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> monotherapy is administered for a 10-day course.</p><p>For patients with ampicillin-resistant <em>E. coli</em>, the choice of definitive therapy is based upon the susceptibility profile. <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefotaxime</a> (if available) is often employed if the isolate is susceptible.</p><p class=\"headingAnchor\" id=\"H943510222\"><span class=\"h4\">Other gram-negative bacilli</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antimicrobial treatment of infections caused by <em>Klebsiella</em>, <em>Proteus</em>, <em>Enterobacter</em>, <em>Serratia</em>, <em>Pseudomonas, Salmonella</em>, or <em>Shigella</em> should be selected based upon the susceptibility profile of the organism. Single-agent therapy is sufficient in most cases.</p><p>Infections caused by multidrug-resistant, gram-negative bacilli, including those caused by extended-spectrum beta-lactamase-producing organisms or those with hyperproduction of beta-lactamases, should be treated with <a href=\"topic.htm?path=meropenem-pediatric-drug-information\" class=\"drug drug_pediatric\">meropenem</a>.</p><p class=\"headingAnchor\" id=\"H943510228\"><span class=\"h4\">Listeria monocytogenes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The combination of <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> is used for initial therapy. Treatment with both agents is more effective than ampicillin alone in vitro and in animal models of <em>Listeria</em> infection. Cephalosporins are <strong>not</strong> active against <em>L. monocytogenes</em>. Duration of therapy usually is 10 days. (See <a href=\"topic.htm?path=treatment-prognosis-and-prevention-of-listeria-monocytogenes-infection#H4\" class=\"medical medical_review\">&quot;Treatment, prognosis, and prevention of Listeria monocytogenes infection&quot;, section on 'Antibiotic regimens'</a>.)</p><p class=\"headingAnchor\" id=\"H943510235\"><span class=\"h4\">Staphylococcus species</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Directed therapy for infection caused by staphylococci is determined by the sensitivity of the isolate to specific antibiotic agents:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Staphylococcus aureus</em> &ndash; <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a>, or in a toxic-appearing infant, vancomycin plus <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a>, should be employed for <em>S. aureus</em> infection until the susceptibility profile is available. The regimen then should be adjusted according to the susceptibility profile:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Methicillin-susceptible <em>S. aureus</em> (MSSA) &ndash; Treatment of MSSA infection should be completed with <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a>. <a href=\"topic.htm?path=cefazolin-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefazolin</a> is an alternative for treatment of most MSSA infections outside the central nervous system (CNS) and not involving endocarditis. (See <a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-in-children-management-and-outcome\" class=\"medical medical_review\">&quot;Staphylococcus aureus bacteremia in children: Management and outcome&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Methicillin-resistant <em>S. aureus</em> (MRSA) &ndash; Treatment should be completed with <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections#H24\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus in children: Treatment of invasive infections&quot;, section on 'Treatment of neonates'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Coagulase-negative staphylococci &ndash; Coagulase-negative staphylococcal infections require treatment with <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>.</p><p/><p class=\"headingAnchor\" id=\"H342331\"><span class=\"h2\">Probable but unproven sepsis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In infants with a negative blood culture but a clinical status that remains concerning for a systemic infection (eg, ongoing temperature instability; ongoing respiratory, cardiocirculatory, or neurologic symptoms not explained by other conditions; or laboratory abnormalities suggestive of sepsis), antibiotic therapy can be extended for as long as a total of 5 to 10 days.</p><p>After 48 hours, the empiric regimen is altered based upon whether or not meningitis has been excluded:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If meningitis has been excluded, the <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> regimen can be changed to 75 <span class=\"nowrap\">mg/kg</span> every 12 hours.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If LP has not been performed, <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> should be continued at a meningitic dose.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Management of infants with CSF pleocytosis <span class=\"nowrap\">and/or</span> positive CSF culture is discussed separately. (See <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Treatment and outcome&quot;</a>.)</p><p/><p>Alternative diagnoses should also be entertained when an infant with suspected sepsis has negative cultures (<a href=\"image.htm?imageKey=PEDS%2F100409\" class=\"graphic graphic_table graphicRef100409 \">table 1</a>). Antibiotics should be discontinued when another diagnosis is established. (See <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H22\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Differential diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Infection unlikely</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Empiric antibiotics are initiated in many infants with maternal risk factors, abnormal laboratory values, <span class=\"nowrap\">and/or</span> mild-to-moderate symptoms that subsequently resolve. Sepsis is unlikely in these infants if they remain well and the blood culture is sterile at 48 hours. Empiric antibiotic therapy should be discontinued after 48 hours in these neonates [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/1,20\" class=\"abstract_t\">1,20</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Response to therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In most cases, symptomatic infants with proven sepsis improve clinically within 24 to 48 hours.</p><p>In infants with bacteremia, a repeat blood culture should be obtained after 24 to 48 hours of therapy to document sterility. Failure to sterilize the bloodstream suggests that the antimicrobial(s) chosen are not active against the infecting pathogen or that there is an unrecognized focus of infection. Consultation with a pediatric infectious disease specialist may be warranted.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">ADJUNCTIVE THERAPIES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following adjunctive immunotherapeutic interventions have been studied in neonatal sepsis, but should <strong>not</strong> be routinely administered, as they have not been shown to conclusively improve outcomes [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/18,19,21\" class=\"abstract_t\">18,19,21</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intravenous immunoglobulin (IVIG) infusions [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/22,23\" class=\"abstract_t\">22,23</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Granulocyte transfusions [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/24\" class=\"abstract_t\">24</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/25,26\" class=\"abstract_t\">25,26</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=pentoxifylline-pediatric-drug-information\" class=\"drug drug_pediatric\">Pentoxifylline</a> [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/27\" class=\"abstract_t\">27</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lactoferrin [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/28\" class=\"abstract_t\">28</a>]</p><p/><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The primary intervention to prevent neonatal sepsis is the use of intrapartum antibiotic prophylaxis (IAP) in mothers with group B streptococcal (GBS) colonization and other risk factors. Although IAP has resulted in a decrease in the incidence of early-onset GBS invasive neonatal infection, it has not had a similar impact on the rate of late-onset GBS disease. (See <a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention\" class=\"medical medical_review\">&quot;Neonatal group B streptococcal disease: Prevention&quot;</a> and <a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants#H7\" class=\"medical medical_review\">&quot;Group B streptococcal infection in neonates and young infants&quot;, section on 'Epidemiology'</a>.)</p><p>Comprehensive prevention of neonatal sepsis will require a multi-interventional program including effective maternal vaccination, reduction in preterm delivery, and limited exposure of term infants to potential pathogens. (See <a href=\"topic.htm?path=vaccines-for-the-prevention-of-group-b-streptococcal-disease\" class=\"medical medical_review\">&quot;Vaccines for the prevention of group B streptococcal disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">OUTCOME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Overall mortality in term and late preterm infants with neonatal sepsis is approximately 2 to 4 percent [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/12,29\" class=\"abstract_t\">12,29</a>]. Mortality estimates vary depending on gestational age of the infant (lower gestational age is associated with higher mortality), pathogen (<em>E. coli </em>is associated with higher mortality than GBS), and sepsis definition (lower mortality rates tend to be reported if infants with culture-negative clinical sepsis are included compared with cases of culture-proven sepsis only).</p><p>Mortality rates for GBS sepsis in term infants after the introduction of IAP and routine use of empirical antibiotic therapy range from 2 to 3 percent for early-onset disease and 1 to 2 percent for late-onset disease. The risk of mortality is higher in infants with birth weight less than 2500 g, absolute neutrophil count less than 1500 <span class=\"nowrap\">cells/microL,</span> hypotension, apnea, and pleural effusion [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/30\" class=\"abstract_t\">30</a>]. (See <a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants#H37\" class=\"medical medical_review\">&quot;Group B streptococcal infection in neonates and young infants&quot;, section on 'Outcome'</a>.)</p><p>The risk of mortality is particularly high in neonates with early-onset sepsis caused by <em>E. coli</em>. Estimated mortality rates for term neonates with <em>E. coli</em> sepsis are 6 to 10 percent [<a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/9,29,31\" class=\"abstract_t\">9,29,31</a>].</p><p class=\"headingAnchor\" id=\"H2672443870\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-sepsis-in-neonates\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Sepsis in neonates&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-group-b-streptococcal-infection-in-pregnant-women-and-neonates\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Group B streptococcal infection in pregnant women and neonates&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=sepsis-in-newborn-babies-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Sepsis in newborn babies (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although the incidence of sepsis in term and late preterm infants is low, the potential for serious adverse outcomes, including death, is of such great consequence that caregivers should have a low threshold for evaluation and treatment for possible sepsis. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Supportive care for symptomatic infants is delivered in an intensive care setting to ensure adequate oxygenation, perfusion, and maintenance of normal fluid and electrolyte balance, especially in severely affected patients. (See <a href=\"#H341853\" class=\"local\">'Supportive care'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Indications for empiric antibiotic therapy include any of the following:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Ill-appearance (see <a href=\"topic.htm?path=approach-to-the-ill-appearing-infant-younger-than-90-days-of-age\" class=\"medical medical_review\">&quot;Approach to the ill-appearing infant (younger than 90 days of age)&quot;</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Concerning symptoms, including temperature instability or respiratory, cardiocirculatory, or neurologic symptoms (see <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H8\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Clinical manifestations'</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Cerebrospinal fluid (CSF) pleocytosis (white blood cell [WBC] cell count of &gt;20 to 30 <span class=\"nowrap\">cells/microL)</span> (<a href=\"image.htm?imageKey=PEDS%2F54464\" class=\"graphic graphic_table graphicRef54464 \">table 2</a>) (see <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-clinical-features-and-diagnosis#H12\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Clinical features and diagnosis&quot;, section on 'Interpretation of CSF'</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Confirmed or suspected maternal chorioamnionitis (see <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H96556694\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Maternal risk factors'</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Positive blood, urine, or CSF culture (see <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H15\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Blood culture'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend suspected neonatal sepsis be treated initially with empiric antibiotic therapy (<a href=\"image.htm?imageKey=PEDS%2F102574\" class=\"graphic graphic_table graphicRef102574 \">table 3</a>) that provides broad coverage for the most likely pathogens (group B<em> Streptococcus</em> [GBS] and gram-negative enteric organisms, including <em>Escherichia coli</em> [<em>E. coli</em>]) (<a href=\"image.htm?imageKey=PEDS%2F61061\" class=\"graphic graphic_table graphicRef61061 \">table 4</a>) (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For neonates with <strong>early-onset sepsis</strong> without an apparent focus, we suggest initial empiric therapy with <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> rather than other agents (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H5\" class=\"local\">'Early-onset sepsis'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For neonates with <strong>late-onset sepsis</strong> without an apparent focus, we suggest the following (see <a href=\"#H6\" class=\"local\">'Late-onset sepsis'</a> above):</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>For neonates admitted from the community, we suggest <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> rather than other agents (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>).</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>For infants who continue to be hospitalized from birth, we suggest <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> rather than other agents (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If the clinical findings suggest a focal source of infection, the empiric antibiotic regimen is modified as follows (<a href=\"image.htm?imageKey=PEDS%2F102574\" class=\"graphic graphic_table graphicRef102574 \">table 3</a>) (see <a href=\"#H943509807\" class=\"local\">'Special circumstances'</a> above):</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>If there is concern of late-onset meningitis, a third-generation cephalosporin (eg, <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a>, if available) is added to the regimen. (See <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome#H4\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Treatment and outcome&quot;, section on 'Empiric therapy'</a>.)</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>If there is concern for pneumonia, acceptable empiric regimens include <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a>, ampicillin and a third-generation cephalosporin (eg, <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefotaxime</a>, if available), <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> and cefotaxime (if available), or vancomycin and gentamicin. (See <a href=\"topic.htm?path=neonatal-pneumonia#H24\" class=\"medical medical_review\">&quot;Neonatal pneumonia&quot;, section on 'Treatment'</a>.)</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>If there is a focus of infection involving the skin, soft tissues, bone, or joints, <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> is substituted for <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> (in toxic-appearing infants, <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a> is also added).</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>If intravascular catheter-related infection is a concern, the empiric regimen consists of <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a>.</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>If an intestinal source for sepsis is suspected, <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a> or <a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">metronidazole</a> is added to the regimen.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antibiotic therapy is altered based upon isolation of the causative agent and its antimicrobial susceptibility pattern. (See <a href=\"#H18750256\" class=\"local\">'Pathogen-specific therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In infants with culture-proven sepsis, the usual course of therapy is 10 days. Longer treatment is warranted if a specific focus of infection is identified (eg, meningitis, osteomyelitis, or septic arthritis). (See <a href=\"#H7\" class=\"local\">'Culture-proven sepsis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In well-appearing infants with negative cultures after 48 hours, empiric antibiotic therapy should be discontinued, as sepsis is unlikely in these infants. (See <a href=\"#H10\" class=\"local\">'Infection unlikely'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most infants with culture-proven sepsis improve clinically within 24 to 48 hours after appropriate antibiotic treatment is started. The response to antibiotic therapy is assessed by a repeat blood culture 24 to 48 hours after initiation of antibiotic therapy. Failure to sterilize the bloodstream suggests either that the antimicrobial(s) chosen are not active against the infecting pathogen or that there is an unrecognized focus of infection. (See <a href=\"#H11\" class=\"local\">'Response to therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The mortality of neonatal sepsis in term infants is less than 10 percent. (See <a href=\"#H16\" class=\"local\">'Outcome'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The primary intervention to prevent neonatal sepsis is the use of intrapartum antibiotic prophylaxis (IAP) in mothers with documented GBS colonization, a previous birth of an infant with GBS disease, or GBS bacteriuria during the current pregnancy. (See <a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention\" class=\"medical medical_review\">&quot;Neonatal group B streptococcal disease: Prevention&quot;</a>.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/1\" class=\"nounderline abstract_t\">Polin RA, Committee on Fetus and Newborn. Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics 2012; 129:1006.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/2\" class=\"nounderline abstract_t\">Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.</a></li><li class=\"breakAll\">Edwards, MS, Baker, CJ. Sepsis in the Newborn. In: Krugman's Infectious Diseases of Children, 11th ed, Gershon, AA, Hotez, PJ, Katz, SL (Eds), Mosby, Philadelphia 2004, p. 545.</li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/4\" class=\"nounderline abstract_t\">Wynn JL, Wong HR, Shanley TP, et al. Time for a neonatal-specific consensus definition for sepsis. Pediatr Crit Care Med 2014; 15:523.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/5\" class=\"nounderline abstract_t\">Raju TN, Higgins RD, Stark AR, Leveno KJ. Optimizing care and outcome for late-preterm (near-term) infants: a summary of the workshop sponsored by the National Institute of Child Health and Human Development. Pediatrics 2006; 118:1207.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Group B streptococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, 2015. p.745.</li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/7\" class=\"nounderline abstract_t\">Rao SC, Ahmed M, Hagan R. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2006; :CD005091.</a></li><li class=\"breakAll\">Medications. In: Guidelines for Acute Care of the Neonate, 22nd ed, Adams JM, Fernandes CJ (Eds), Baylor College of Medicine, Houston, TX 2014. p.89.</li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/9\" class=\"nounderline abstract_t\">Stoll BJ, Hansen NI, S&aacute;nchez PJ, et al. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics 2011; 127:817.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/10\" class=\"nounderline abstract_t\">Muller-Pebody B, Johnson AP, Heath PT, et al. Empirical treatment of neonatal sepsis: are the current guidelines adequate? Arch Dis Child Fetal Neonatal Ed 2011; 96:F4.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/11\" class=\"nounderline abstract_t\">Maayan-Metzger A, Barzilai A, Keller N, Kuint J. Are the &quot;good old&quot; antibiotics still appropriate for early-onset neonatal sepsis? A 10 year survey. Isr Med Assoc J 2009; 11:138.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/12\" class=\"nounderline abstract_t\">Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics 2006; 117:67.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Escherichia coli and other Gram-negative bacilli (septicemia and meningitis in neonates). In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.340.</li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/14\" class=\"nounderline abstract_t\">Gulian JM, Dalmasso C, Gonard V. Interaction of beta-lactam antibiotics on bilirubin-albumin complex: comparison by three methods, total bilirubin, unbound bilirubin and erythrocyte-bound bilirubin. Chemotherapy 1990; 36:91.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/15\" class=\"nounderline abstract_t\">Martin E, Fanconi S, K&auml;lin P, et al. Ceftriaxone--bilirubin-albumin interactions in the neonate: an in vivo study. Eur J Pediatr 1993; 152:530.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Tables of antibacterial drug dosages, Table 4.2. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.882.</li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/17\" class=\"nounderline abstract_t\">Fortunov RM, Hulten KG, Hammerman WA, et al. Community-acquired Staphylococcus aureus infections in term and near-term previously healthy neonates. Pediatrics 2006; 118:874.</a></li><li class=\"breakAll\">Nizet V, Klein JO. Bacterial sepsis and meningitis. In: Infectious diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, et al (Eds), WB Saunders, Philadelphia 2010. p.222.</li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/19\" class=\"nounderline abstract_t\">Gerdes JS. Diagnosis and management of bacterial infections in the neonate. Pediatr Clin North Am 2004; 51:939.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/20\" class=\"nounderline abstract_t\">Polin RA, Watterberg K, Benitz W, Eichenwald E. The conundrum of early-onset sepsis. Pediatrics 2014; 133:1122.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/21\" class=\"nounderline abstract_t\">Cohen-Wolkowiez M, Benjamin DK Jr, Capparelli E. Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis. Curr Opin Pediatr 2009; 21:177.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/22\" class=\"nounderline abstract_t\">INIS Collaborative Group, Brocklehurst P, Farrell B, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med 2011; 365:1201.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/23\" class=\"nounderline abstract_t\">Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev 2015; :CD001239.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/24\" class=\"nounderline abstract_t\">Pammi M, Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia. Cochrane Database Syst Rev 2011; :CD003956.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/25\" class=\"nounderline abstract_t\">Schibler KR, Osborne KA, Leung LY, et al. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics 1998; 102:6.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/26\" class=\"nounderline abstract_t\">Carr R, Modi N, Dor&eacute; C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev 2003; :CD003066.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/27\" class=\"nounderline abstract_t\">Pammi M, Haque KN. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev 2015; :CD004205.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/28\" class=\"nounderline abstract_t\">Pammi M, Suresh G. Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2017; 6:CD007137.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/29\" class=\"nounderline abstract_t\">Weston EJ, Pondo T, Lewis MM, et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. Pediatr Infect Dis J 2011; 30:937.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/30\" class=\"nounderline abstract_t\">Payne NR, Burke BA, Day DL, et al. Correlation of clinical and pathologic findings in early onset neonatal group B streptococcal infection with disease severity and prediction of outcome. Pediatr Infect Dis J 1988; 7:836.</a></li><li><a href=\"https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/abstract/31\" class=\"nounderline abstract_t\">Escobar GJ, Li DK, Armstrong MA, et al. Neonatal sepsis workups in infants &gt;/=2000 grams at birth: A population-based study. Pediatrics 2000; 106:256.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5046 Version 31.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H17\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">TERMINOLOGY</a></li><li><a href=\"#H341853\" id=\"outline-link-H341853\">SUPPORTIVE CARE</a></li><li><a href=\"#H943510014\" id=\"outline-link-H943510014\">ONGOING DIAGNOSTIC EVALUATION</a><ul><li><a href=\"#H878363033\" id=\"outline-link-H878363033\">Other diagnostic considerations</a></li><li><a href=\"#H943510021\" id=\"outline-link-H943510021\">Lumbar puncture</a></li></ul></li><li><a href=\"#H3\" id=\"outline-link-H3\">ANTIBIOTIC THERAPY</a><ul><li><a href=\"#H943509421\" id=\"outline-link-H943509421\">Whom to treat</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Initial empiric therapy</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">- Early-onset sepsis</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">- Late-onset sepsis</a><ul><li><a href=\"#H943509792\" id=\"outline-link-H943509792\">Admitted from the community</a></li><li><a href=\"#H943509801\" id=\"outline-link-H943509801\">Hospitalized since birth</a></li></ul></li><li><a href=\"#H943509807\" id=\"outline-link-H943509807\">- Special circumstances</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">Culture-proven sepsis</a><ul><li><a href=\"#H18750256\" id=\"outline-link-H18750256\">- Pathogen-specific therapy</a><ul><li><a href=\"#H943510209\" id=\"outline-link-H943510209\">Group B Streptococcus</a></li><li><a href=\"#H943510215\" id=\"outline-link-H943510215\">Escherichia coli</a></li><li><a href=\"#H943510222\" id=\"outline-link-H943510222\">Other gram-negative bacilli</a></li><li><a href=\"#H943510228\" id=\"outline-link-H943510228\">Listeria monocytogenes</a></li><li><a href=\"#H943510235\" id=\"outline-link-H943510235\">Staphylococcus species</a></li></ul></li></ul></li><li><a href=\"#H342331\" id=\"outline-link-H342331\">Probable but unproven sepsis</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Infection unlikely</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Response to therapy</a></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">ADJUNCTIVE THERAPIES</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">PREVENTION</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">OUTCOME</a></li><li><a href=\"#H2672443870\" id=\"outline-link-H2672443870\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H164795296\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/5046|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/100409\" class=\"graphic graphic_table\">- Neonatal sepsis differential diagnosis</a></li><li><a href=\"image.htm?imageKey=PEDS/54464\" class=\"graphic graphic_table\">- Normal cerebrospinal fluid indices neonate</a></li><li><a href=\"image.htm?imageKey=PEDS/102574\" class=\"graphic graphic_table\">- Antibiotic regimens for neonatal sepsis</a></li><li><a href=\"image.htm?imageKey=PEDS/61061\" class=\"graphic graphic_table\">- Bacteria sepsis term infant</a></li><li><a href=\"image.htm?imageKey=ID/66906\" class=\"graphic graphic_table\">- Neonatal GBS infection rx</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-ill-appearing-infant-younger-than-90-days-of-age\" class=\"medical medical_review\">Approach to the ill-appearing infant (younger than 90 days of age)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-clinical-features-and-diagnosis\" class=\"medical medical_review\">Bacterial meningitis in the neonate: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome\" class=\"medical medical_review\">Bacterial meningitis in the neonate: Treatment and outcome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation\" class=\"medical medical_review\">Clinical features and diagnosis of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=etiology-clinical-manifestations-evaluation-and-management-of-neonatal-shock\" class=\"medical medical_review\">Etiology, clinical manifestations, evaluation, and management of neonatal shock</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=febrile-infant-younger-than-90-days-of-age-management\" class=\"medical medical_review\">Febrile infant (younger than 90 days of age): Management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fluid-and-electrolyte-therapy-in-newborns\" class=\"medical medical_review\">Fluid and electrolyte therapy in newborns</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=group-b-streptococcal-infection-in-neonates-and-young-infants\" class=\"medical medical_review\">Group B streptococcal infection in neonates and young infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=late-preterm-infants\" class=\"medical medical_review\">Late preterm infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-and-outcome-of-neonatal-hypoglycemia\" class=\"medical medical_review\">Management and outcome of neonatal hypoglycemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis\" class=\"medical medical_review\">Management of the infant whose mother has received group B streptococcal chemoprophylaxis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mechanical-ventilation-in-neonates\" class=\"medical medical_review\">Mechanical ventilation in neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus in children: Treatment of invasive infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention\" class=\"medical medical_review\">Neonatal group B streptococcal disease: Prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-pneumonia\" class=\"medical medical_review\">Neonatal pneumonia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=noninvasive-oxygen-delivery-and-oxygen-monitoring-in-the-newborn\" class=\"medical medical_review\">Noninvasive oxygen delivery and oxygen monitoring in the newborn</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sepsis-in-newborn-babies-the-basics\" class=\"medical medical_basics\">Patient education: Sepsis in newborn babies (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-group-b-streptococcal-infection-in-pregnant-women-and-neonates\" class=\"medical medical_society_guidelines\">Society guideline links: Group B streptococcal infection in pregnant women and neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-sepsis-in-neonates\" class=\"medical medical_society_guidelines\">Society guideline links: Sepsis in neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-in-children-management-and-outcome\" class=\"medical medical_review\">Staphylococcus aureus bacteremia in children: Management and outcome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation\" class=\"medical medical_review\">Treatment and prevention of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-prognosis-and-prevention-of-listeria-monocytogenes-infection\" class=\"medical medical_review\">Treatment, prognosis, and prevention of Listeria monocytogenes infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vaccines-for-the-prevention-of-group-b-streptococcal-disease\" class=\"medical medical_review\">Vaccines for the prevention of group B streptococcal disease</a></li></ul></div></div>","javascript":null}